Compare ProShares Ultra Gold ETF (UGL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Gold ETF vs Zimmer Biomet Holdings Inc — how do they compare? ProShares Ultra Gold ETF trades at $46.47 (market cap $716.59M), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 23.7× ProShares Ultra Gold ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra Gold ETF for 23 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| UGL | ZBH | |
|---|---|---|
Market Cap | $716.59M | $16.95B |
Volume | 2,592,878 | 2,505,240 |
Sector | Leveraged / Inverse | Health |
52-Week High | $85.62 | $103.98 |
52-Week Low | $42.79 | $79.58 |
Typical Hold Time | 23 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UGL is trading at $46.45, up 4.55% today, but faces significant technical headwinds with a bearish overall signal. The stock shows neutral momentum oscillators but bearish moving averages, with key resistance at $46. Current financial ratios are unavailable, limiting fundamental assessment. Recent gold market volatility driven by Treasury yields and Fed policy expectations creates uncertainty for gold-related equities.
The outlook remains cautious given technical weakness and macroeconomic pressures on gold prices. Investment opportunity exists for contrarian investors if gold regains momentum, but risks include persistent rate hike expectations and dollar strength. Stock-specific fundamentals require verification through SEC filings for proper valuation assessment.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
